Preface |
|
v | |
Residues of veterinary drugs |
|
|
|
3 | (36) |
|
|
4 | (1) |
|
|
5 | (22) |
|
|
5 | (4) |
|
2.1.1 Absorption, distribution and excretion |
|
|
5 | (1) |
|
|
5 | (1) |
|
|
6 | (2) |
|
|
8 | (1) |
|
2.2 Toxicological studies |
|
|
9 | (14) |
|
|
9 | (1) |
|
|
9 | (1) |
|
|
9 | (1) |
|
|
9 | (1) |
|
2.2.2 Short-term studies of toxicity |
|
|
10 | (1) |
|
|
10 | (1) |
|
|
11 | (1) |
|
|
12 | (1) |
|
2.2.3 Long-term studies of toxicity and carcinogenicity |
|
|
12 | (1) |
|
|
12 | (1) |
|
2.2.5 Reproductive and developmental toxicity |
|
|
13 | (1) |
|
|
13 | (1) |
|
|
16 | (1) |
|
2.2.6 Special studies on microbiological effects |
|
|
17 | (6) |
|
2.3 Observations in humans |
|
|
23 | (4) |
|
2.3.1 Gastrointestinal effects |
|
|
23 | (1) |
|
2.3.2 Allergen and immune response |
|
|
23 | (1) |
|
|
24 | (1) |
|
2.3.4 Reproductive toxicity |
|
|
25 | (2) |
|
|
27 | (4) |
|
|
27 | (1) |
|
|
27 | (3) |
|
|
30 | (1) |
|
|
31 | (1) |
|
|
32 | (7) |
|
|
39 | (26) |
|
|
40 | (1) |
|
|
41 | (14) |
|
|
41 | (1) |
|
2.1.1 Absorption, distribution and excretion |
|
|
41 | (1) |
|
|
41 | (1) |
|
|
41 | (1) |
|
|
42 | (1) |
|
2.2 Toxicological studies |
|
|
42 | (13) |
|
|
42 | (1) |
|
|
42 | (1) |
|
b Irritation and sensitization |
|
|
43 | (1) |
|
2.2.2 Short-term studies of toxicity |
|
|
44 | (1) |
|
|
44 | (1) |
|
|
44 | (1) |
|
|
45 | (1) |
|
|
46 | (1) |
|
|
46 | (1) |
|
|
47 | (1) |
|
2.2.3 Long-term studies of toxicity and carcinogenicity |
|
|
47 | (1) |
|
|
47 | (1) |
|
|
47 | (1) |
|
|
48 | (1) |
|
2.2.5 Reproductive and developmental toxicity |
|
|
48 | (1) |
|
a Multigeneration studies in rats |
|
|
48 | (1) |
|
b Reproductive toxicity in pigs |
|
|
49 | (1) |
|
|
49 | (1) |
|
|
50 | (1) |
|
a Gastrointestinal irritation |
|
|
50 | (1) |
|
|
50 | (1) |
|
|
50 | (1) |
|
|
50 | (1) |
|
e Microbiological effects |
|
|
51 | (4) |
|
2.3 Observations in humans |
|
|
55 | (1) |
|
|
55 | (5) |
|
|
55 | (1) |
|
|
55 | (4) |
|
|
59 | (1) |
|
|
60 | (1) |
|
|
60 | (5) |
|
|
65 | (54) |
|
|
66 | (1) |
|
|
67 | (37) |
|
|
67 | (7) |
|
2.1.1 Absorption, distribution and excretion |
|
|
67 | (1) |
|
|
67 | (1) |
|
|
69 | (1) |
|
|
69 | (1) |
|
|
70 | (1) |
|
|
71 | (1) |
|
2.1.3 Effects on enzymes and other biochemical parameters |
|
|
72 | (2) |
|
2.2 Toxicological studies |
|
|
74 | (26) |
|
|
74 | (1) |
|
a Single-dose toxicity studies |
|
|
74 | (1) |
|
|
76 | (1) |
|
|
76 | (1) |
|
|
77 | (1) |
|
2.2.2 Short-term studies of toxicity |
|
|
77 | (1) |
|
|
77 | (1) |
|
|
88 | (5) |
|
2.2.3 Long-term studies of toxicity and carcinogenicity |
|
|
93 | (1) |
|
|
93 | (1) |
|
2.2.5 Reproductive and developmental toxicity |
|
|
94 | (1) |
|
a Multigeneration studies |
|
|
94 | (1) |
|
|
96 | (3) |
|
|
99 | (1) |
|
a Structural toxicity alerts for derquantel and related impurities |
|
|
99 | (1) |
|
|
99 | (1) |
|
c Microbiological effects |
|
|
100 | (1) |
|
2.3 Toxicological studies with derquantel/abamectin (Startect) |
|
|
100 | (4) |
|
|
100 | (1) |
|
2.3.2 Short-term studies of toxicity |
|
|
101 | (3) |
|
2.4 Observations in humans |
|
|
104 | (1) |
|
|
104 | (9) |
|
|
104 | (2) |
|
|
106 | (7) |
|
|
113 | (1) |
|
|
113 | (1) |
|
|
113 | (6) |
|
|
119 | (40) |
|
|
120 | (1) |
|
|
121 | (27) |
|
|
121 | (8) |
|
2.1.1 Absorption, distribution and excretion |
|
|
121 | (1) |
|
|
121 | (1) |
|
|
122 | (1) |
|
|
123 | (1) |
|
d Protein binding in vitro |
|
|
123 | (1) |
|
|
124 | (1) |
|
|
124 | (1) |
|
|
125 | (1) |
|
|
128 | (1) |
|
2.1.3 Effects on enzymes and other biochemical parameters |
|
|
128 | (1) |
|
2.2 Toxicological studies |
|
|
129 | (19) |
|
|
129 | (1) |
|
2.2.2 Short-term studies of toxicity |
|
|
129 | (1) |
|
|
129 | (1) |
|
|
131 | (1) |
|
|
134 | (1) |
|
d Target species: Sheep and Iamb |
|
|
139 | (1) |
|
2.2.3 Long-term studies of toxicity and carcinogenicity |
|
|
139 | (2) |
|
|
141 | (2) |
|
2.2.5 Reproductive and developmental toxicity |
|
|
143 | (1) |
|
a Multigeneration studies |
|
|
143 | (1) |
|
|
145 | (2) |
|
|
147 | (1) |
|
a Cardiovascular and respiratory end-points |
|
|
147 | (1) |
|
|
147 | (1) |
|
c Gastrointestinal end-points |
|
|
147 | (1) |
|
|
148 | (1) |
|
e Microbiological effects |
|
|
148 | (1) |
|
2.3 Observations in humans |
|
|
148 | (1) |
|
|
148 | (6) |
|
|
148 | (1) |
|
|
149 | (4) |
|
|
153 | (1) |
|
|
154 | (1) |
|
|
154 | |
Annexes |
|
|
Annex 1 Reports and other documents resulting from previous meetings of the Joint FAO/WHO Expert Committee on Food Additives |
|
|
159 | (12) |
|
Annex 2 Abbreviations used in the monographs |
|
|
171 | (2) |
|
Annex 3 Participants in the seventy-fifth meeting of the Joint FAO/WHO Expert Committee on Food Additives |
|
|
173 | (2) |
|
Annex 4 Recommendations on compounds on the agenda and further information required |
|
|
175 | |